1128-56-9

Usage

Uses

Used in Medicinal Chemistry:
1-Phenyl-3-aminopyrazole is used as a building block for the synthesis of various pharmaceuticals and bioactive molecules, leveraging its structural features to enhance the therapeutic potential of new drug candidates.
Used in Chemical Synthesis:
1-Phenyl-3-aminopyrazole is utilized in the development of new materials and chemical processes, taking advantage of its reactivity and functional groups to create novel compounds with specific applications.
Used in Scientific Research:
1-Phenyl-3-aminopyrazole serves as a subject of interest in scientific research, where its properties and potential uses are explored to advance understanding in organic chemistry and related fields.

InChI:InChI=1/C9H9N3/c10-9-6-7-12(11-9)8-4-2-1-3-5-8/h1-7H,(H2,10,11)

Upstream product

• 2601-89-0 2,3-dichloropropionitrile 
• 100-63-0 phenylhydrazine 
• 108-86-1 bromobenzene 
• 1820-80-0 3-aminopyrazole 
• 591-50-4 iodobenzene 
• 60838-50-8 3-methoxy-2-propenenitrile 
• 59-88-1 phenylhydrazine hydrochloride 
• 3314-35-0 3-Amino-1-phenyl-2-pyrazoline 
• 7732-18-5 water 
• 61310-53-0 3-ethoxyacrylonitrile 
• 458561-89-2 1-phenyl-1H-pyrazole-3-carbonyl azide 
• 509077-92-3 1-phenyl-1H-pyrazole-3-carboxylic acid hydrazide 
• 4747-46-0 1-phenyl-1H-pyrazole-3-carboxylic acid 
• 920-37-6 2-Chloroacrylonitrile 

Downstream Products

• 2753-56-2 N-(1-phenyl-1H-pyrazol-3-yl)-acetamide 
• 88569-93-1 5-chloromethyl-1-phenyl-1H,7H-pyrazolo<1,5-a>pyrimidine-7-one 
• 17436-80-5 6,7-Dihydro-4-methyl-6-oxo-2-phenyl-pyrazolo<3,4-b>pyridin 
• 64748-64-7 1,5-diphenyl-1H-pyrazolo[1,5-a]pyrimidin-7-one 
• 71998-98-6 1-phenyl-3-(4-dimethylaminophenylazo)pyrazole 
• 92133-80-7 4-Methyl-N-(1-phenyl-1H-pyrazol-3-yl)-benzenesulfonamide 
• 87949-09-5 N-(1-phenyl-1H-pyrazol-3-yl)aminomethylenemalonic acid, diethyl ester 
• 127107-30-6 3-amino-1-phenylpyrazole hydrochloride 
• 898567-89-0 5-nitro-2-phenyl-2H-pyrazolo [3,4-b]pyridine 
• 1001090-98-7 2-phenyl-4-(4-methoxyphenyl)-5H-indeno[1,2-b]pyrazolo[4,3-e]pyridin-5-one 
• 328232-93-5 trans-3-oxo-N-(1-phenyl-1H-pyrazol-3-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 425644-16-2 N-(1-phenylpyrazol-3-yl)-N-(1-phenethyl-4-piperidyl)amine 
• 425644-15-1 N-(1-phenylpyrazol-3-yl)-N-(1-benzyl-4-piperidyl)amine 

Relevant academic research and scientific papers

Copper-Catalyzed N1 Coupling of 3-Aminoindazoles and Related Aminoazoles with Aryl Bromides

The N1-selective arylation of 3-aminoindazoles using copper catalysis is herein reported. The reaction uses readily accessible aryl bromides as coupling partners, including those from heterocycles, and allows easy access to a broad variety of substituted 3-aminoindazoles. The methodology was also examined on other aminoazoles of interest for the pharmaceutical industry.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

HETEROCYCLIC COMPOUNDS AND USE OF SAME

Novel heterocyclic compounds are provided which display useful efficacy in the treatment of diseases caused by trypanosomatids. Particularly, the compounds of the invention are useful in the treatment of HAT and/or Chagas disease and/or Animal African trypanosomiasis (AAT).

ANTI-INFECTIVE COMPOUNDS

The present invention relates to small molecule compounds having the general formula (I): wherein A is a moiety selected from the group consisting of formulae (A) to (K) and their use in the treatment of bacterial infections, in particular Tuberculosis.

Copper(I)/Copper(II)-Assisted Tandem Catalysis: The Case Study of Ullmann/Chan-Evans-Lam N1,N3-Diarylation of 3-Aminopyrazole

Unprecedented CuI/CuII-assisted tandem catalysis allowing an Ullmann/Chan-Evans-Lam sequence was achieved. This three-component, one-pot reaction triggered by a change in the oxidation state of the metal leads to the selective N1,N3-diarylation of 3-aminopyrazole. This new method should be a valuable tool for small-molecule drug discovery that requires suitable regio- and/or chemoselective strategies for the N-arylation of nitrogen-containing heterocycles. Tandem power: The first assisted tandem copper-catalyzed process, triggered by a change in the oxidation state of the metal, is developed to allow a one-pot Ullman/Chan-Evans-Lam sequence leading to the selective N1,N3-diarylation of 3-aminopyrazole.

PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention provides a pyrazole compound of the following general Formula [1b] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use wherein each symbol is the same as defined in the description

Regiocontrolled synthesis of 3- and 5-aminopyrazoles, pyrazolo[3,4-d] pyrimidines, pyrazolo[3,4-b]pyridines and pyrazolo[3,4-b]quinolinones as MAPK inhibitors

Microwave irradiation of a hydrazine and 3-methoxyacrylonitrile, ethoxymethylenemalononitrile or ethyl acetoacetate provides rapid access to 3- or 5-substituted pyrazoles in excellent yield and with total regiocontrol in a process that can be switched from one regioisomer to the other by choice of conditions. Subsequent reaction, either by microwave-assisted hydrolysis and cyclocondensation with formamide, Hantzsch-type three-component reaction with an aldehyde and ketone, or by cyclocondensation with 2-nitrobenzaldehyde, provides the pyrazolo[3,4-d]pyrimidine, pyrazolo[3,4-b]pyridine or pyrazolo[3,4-b] quinolin-4-one framework, respectively, of inhibitors of mitogen-activated protein kinases.